GSM: The Menopause Symptom Nobody Names

What Is Genitourinary Syndrome of Menopause (GSM)?

Genitourinary syndrome of menopause, or GSM, affects approximately 27% to 84% of postmenopausal women and is likely underdiagnosed, according to the 2020 position statement from The North American Menopause Society (NAMS). That is an unusually wide range for a single condition — a sign of how often it goes unnamed in an appointment, not a sign that it is rare.

GSM is the umbrella term for changes in the vulva, vagina, bladder, and urethra that develop as estrogen declines. The name replaced "vulvovaginal atrophy," an older term that covered only part of the picture, when menopause and sexual-health societies agreed on the new definition in the last decade. The symptom list is broader than most women expect: dryness, irritation or burning, discomfort with sex, and urinary urgency, frequency, or recurrent infections can all trace back to the same underlying shift.

What makes GSM different from a single, easy-to-name symptom is exactly that breadth. A woman might mention dryness to one provider, urinary urgency to another, and never connect the two — when in an appointment focused on GSM specifically, both would be part of the same conversation. Naming the syndrome, rather than describing each symptom in isolation, is often the first step toward a plan that actually fits.

Why GSM Is Progressive — and So Often Missed

Unlike hot flashes, which tend to ease with time on their own, GSM tends to move the other way. A peer-reviewed review of GSM epidemiology and physiology describes how declining estrogen thins the vaginal and urinary tract lining, reduces local blood flow, and shifts the resident microbial balance — changes that tend to continue rather than resolve on their own.

Part of why it goes undiagnosed is ordinary awkwardness: women often assume the symptoms are just "getting older" and don't bring them up, and a routine appointment may not leave room for the question. Vaginal symptoms and urinary symptoms are also frequently raised in separate conversations, if at all, so one shared root cause can hide behind two unrelated-sounding complaints.

Discomfort with sex can carry its own layer of hesitation, too — some women bring it up with a partner before they ever mention it to a provider, and some don't bring it up at all. None of that awkwardness changes how common the underlying shift is, or how directly a provider can help once it's named.

The Urinary Piece: GSM and Recurrent UTIs

The bladder, urethra, and vagina share embryonic tissue origin, so they respond to the same hormonal shift together. A review of the urinary manifestations of GSM walks through how estrogen decline changes bladder-lining tissue and the vaginal environment at the same time — part of why UTIs tend to become more common after menopause.

If urinary changes and vaginal dryness are showing up around the same window of time, that overlap is worth naming directly at an appointment rather than describing them as two separate issues — providers often manage the two together once the connection is on the table.

What the NAMS Position Statement Says About Options

The NAMS statement lays out a stepped approach by severity. For milder symptoms, over-the-counter vaginal moisturizers and lubricants are listed among the first options worth trying. For moderate to severe symptoms, it discusses prescription routes — low-dose vaginal estrogen, vaginal DHEA, and the medication ospemifene — with pelvic floor physical therapy as a complementary option some providers recommend alongside them.

None of this is meant as a self-diagnosis checklist. It is a starting point for a specific conversation: what is actually happening, how significant it is, and which option, or combination, a qualified provider thinks fits your history. Severity matters here — the statement is explicit that choice of therapy depends on how pronounced the symptoms are and on the individual woman's health history, which is exactly the kind of judgment a checklist can't make for you. The Office on Women's Health and The Menopause Society's patient guidance are both worth reading before that visit.

Where a pH-Matched Lubricant Fits

Because moisturizers and lubricants sit at the mildest, first-line end of that list, the chemistry of what you actually use there matters. Desert Harvest's Aloe Glide is an FDA-cleared medical device, not a dietary supplement, formulated at pH 4.5 and iso-osmolar (308) — matching the vagina's natural chemistry instead of disrupting it — and compatible with both latex and polyisoprene condoms.

Aloe Glide does not act on the hormonal cause of GSM — no lubricant or moisturizer does. What it offers is a moisturizer and lubricant formulated with that chemistry in mind, one to raise alongside the other options above with your provider. For background on the ingredient behind it, see the science of Aloe Vera for intimate skin, or browse the full pelvic and sexual wellness collection.

If any of this sounds familiar — dryness, discomfort, or urinary changes that started around perimenopause or menopause — it is worth saying out loud at your next appointment instead of filing it under ordinary aging. Bring specifics: when it started, what makes it better or worse, and whether urinary symptoms are part of the picture, so your provider can help sort through the options that fit you. For the wider picture, from the stages to symptoms by body system, our menopause guide brings it together.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to your health regimen.